Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

ABBV AbbVie Inc

166,41

1,75 (1,06%)

20 Apr 2024 - Geschlossen

Verzögert um 15 Minuten

Certification by the Exchange Approving Securities for Listing (cert)

This regulatory filing also includes additional resources:
ABBV8A092619.pdf

AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mär 2024 bis Apr 2024

Click Here for more AbbVie Charts.

AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2023 bis Apr 2024

Click Here for more AbbVie Charts.

News Abbvie Inc.

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Donnerstag 18 April 2024 (2 Tage vor) • PR Newswire (US)

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
Freitag 12 April 2024 (1 Woche vor) • PR Newswire (US)

SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
Dienstag 9 April 2024 (2 Wochen vor) • PR Newswire (US)

AbbVie to Host First-Quarter 2024 Earnings Conference Call
Donnerstag 4 April 2024 (2 Wochen vor) • PR Newswire (US)

Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
Mittwoch 3 April 2024 (2 Wochen vor) • PR Newswire (US)

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
Montag 1 April 2024 (3 Wochen vor) • GlobeNewswire Inc.

Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News
Dienstag 26 März 2024 (4 Wochen vor) • IH Market News

Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
Montag 25 März 2024 (4 Wochen vor) • PR Newswire (US)

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Montag 25 März 2024 (4 Wochen vor) • PR Newswire (US)

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Montag 25 März 2024 (4 Wochen vor) • GlobeNewswire Inc.

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
Freitag 22 März 2024 (4 Wochen vor) • PR Newswire (US)

ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
Donnerstag 21 März 2024 (4 Wochen vor) • PR Newswire (US)

Weitere Abbvie Inc. News-Artikel

Deutsche Telekom (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen